Floatz Rating
B58/100
Confidence
Indicative
Sponsor
Peking University Cancer Hospital & Institute
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
54High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06424626CT.gov A Trial of AK104 or AK112 in Combination With Axitinib in Patients With Metastatic Mucosal Melanoma | — | Not Yet Recruiting | — | — | — |
NCT05070221CT.gov Study of Oncolytic Virus in Combination With HX-008 and Axitinib in Melanoma Patients With Liver Metastasis | — | Unknown | — | — | — |
NCT04996823CT.gov Axitinib + Ipilimumab in Advanced Melanoma | — | Recruiting | — | — | — |
NCT04493203CT.gov Nivolumab Plus Axitinib in Patients With Anti-PD1 Refractory Advanced Melanoma | — | Completed | — | — | — |
NCT04640545CT.gov A Study to Assess LBL-007 in Combination With Toripalimab and Axitinib Tablets Subjects With Advanced Melanoma | — | Completed | — | — | — |
NCT01533948CT.gov Axitinib in Treating Patients With Melanoma That is Metastatic or Cannot Be Removed by Surgery | — | Terminated | — | — | — |
NCT01321437CT.gov Study of the Anti-Angiogenesis Agent Axitinib in Patients With Stage III Malignant Melanoma | — | Completed | — | — | — |
NCT01174238CT.gov A Two Arm Trial of Axitinib and Carboplatin/Paclitaxel in Melanoma | — | Completed | — | — | — |
NCT00094107CT.gov Anti-Angiogenesis Agent AG-013736 In Patients With Metastatic Melanoma | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Melanoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Axitinib (this asset) | Peking University Cancer Hospital & Institute | P2 | B · 58 |
| Gm-Csf | Ultimovacs ASA | P4 | BBB |
| Sargramostim | Mayo Clinic | P3 | BBB |
| Cediranib | M.D. Anderson Cancer Center | P3 | BBB |
| Ifa | Craig L Slingluff, Jr | P2 | BB |
| Cyclophosphamide | Primmune Therapeutics, Inc. | P4 | BB |
| Temsirolimus | University of Regensburg | P2 | BB |
| Tebentafusp | Immunocore Ltd | P3 | BB |
| Dacarbazine | Suzhou BlueHorse Therapeutics Co., Ltd. | P3 | BB |
+42 more in the Melanoma cohort
Other indications for Axitinib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Kidney Neoplasm | — | P3 | BB · 69 |
| Renal Cell Carcinoma | — | P4 | BB · 67 |
| Kidney Cancer | — | P4 | BB · 66 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Axitinib in Melanoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/axitinib-melanoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →